Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations
- 15 March 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (8) , 1721-1729
Abstract
Rationale: Treatment initiation or intensification to prevent exacerbation of chronic obstructive pulmonary disease (COPD) is based on the identification of patients with high exacerbation risk. The commonly used high-risk category of at least 2 moderate or 1 severe exacerbation within the prior 12 months has limited supporting evidence. Objective: To test the discriminative performance and assess the clinical utility of various COPD exacerbation categories for predicting future exacerbations. Methods: In the COPDGene and NOVELTY cohorts, for each 1-year and 2-year recall periods, we estimated 6 distinct categories of exacerbation frequencies (based on distinct combinations of the number of moderate and severe events), each ascertained in 3 ways: within 1 year, in each of 2 consecutive years, and over a rolling combined 2-year period. We estimated the area under the receiver operating characteristic curve (AUC) and net benefit to evaluate, respectively, the discriminative performance and clinical utility of the resulting 18 categories for predicting the occurrence of two moderate or one severe exacerbation in the next 12 months. Measurements and Main Results: In both COPDGene (n = 3,035) and NOVELTY (n = 3,080), the category of any moderate or severe exacerbation in the past two years had the highest AUC (COPDGene: 0.69, 95%CI 0.67–0.71; NOVELTY: 0.87, 95%CI 0.85–0.88) for predicting the outcome. The AUC was significantly higher than that of the current standard of care of ≥ 2 moderate or ≥ 1 severe exacerbations in the past year (ΔAUC = 0.03 in COPDGene and 0.12 in NOVELTY; both P < .001). In net benefit analysis, exacerbation patterns defined over rolling two-year windows provided the highest net benefit across a clinically relevant treatment threshold range of 5% to 30%. Conclusions: At least 1 moderate or 1 severe exacerbation over the previous 2 years has the highest discrimination and confers the highest clinical utility for predicting high COPD exacerbation risk.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL151421)
- National Heart, Lung, and Blood Institute (U01 HL089897)
- National Heart, Lung, and Blood Institute (U01 HL089856)
- National Institutes of Health (75N92023D00011)
- Canadian Institutes of Health Research (PHT 178432)
- COPD Foundation
This publication has 30 references indexed in Scilit:
- GOLD COPD Exacerbation History Categories and Disease OutcomesJAMA Network Open, 2024
- Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung diseaseJournal of Clinical Epidemiology, 2024
- The Hidden and Unchecked Judgement Calls When Using Exacerbation History for Managing COPDArchivos de Bronconeumología, 2022
- Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estableArchivos de Bronconeumología, 2022
- Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction programCurrent Opinion in Pulmonary Medicine, 2018
- Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohortThe Lancet Respiratory Medicine, 2017
- Effect of a single exacerbation on decline in lung function in COPDRespiratory Medicine, 2017
- Decision Curve AnalysisJAMA, 2015
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society Series B: Statistical Methodology, 1995